

## PRESS RELEASE

### Elanix Biotechnologies AG to Present at German Equity Forum 2017

**Berlin, Germany and Nyon, Switzerland, November 23, 2017** –[Elanix Biotechnologies AG](#) (“Company”), a developer of tissue regeneration products and specialty cosmetics in dermatology and gynecology, today announced that CEO, Tomas Svoboda, will present a corporate overview at the upcoming German Equity Forum 2017 being held November 27-29, 2017 at the Sheraton Frankfurt Airport Hotel & Conference Center in Frankfurt am Main, Germany. The presentation is scheduled for Tuesday, 28 November at 18:00 CET in the Oslo Room.

“We have made significant corporate strides this year in terms of commercial achievements and R&D developments. In particular, we launched our topical women’s health cream, GYNrepair, across Europe, which is supported with an adherence mobile app for users. With the establishment of a logistics center for storage and shipping, we have been able to get closer to point of sales, which complements the leverage we are able to obtain through an e-commerce platform to reach customers directly.

On the R&D side, our partner Transwell Biotech started treatment of patients with skin graft donor site wounds (DSW) in a Phase I/II clinical trial with TWB-103. The study is being conducted in Taiwan and Japan. TWB-103 is a novel gel formulation developed by Transwell Biotech using skin fibroblast progenitor cells provided by Elanix. The start of this trial is a significant milestone in our plan to build a regenerative medicine franchise in acute wound healing based on our proprietary progenitor cell technology, Firstcover. This gets us one step closer to introducing an acute wound care treatment to the market, which could benefit over two million patients worldwide that are hospitalised for burns annually,” stated Tomas Svoboda, CEO of Elanix Biotechnologies.

The German Equity Forum hosted by German Stock Exchange “Deutsche Börse” is Europe's largest and most important capital market event. For more information about the event program, time frame and venue, please see the event website at [www.eigenkapitalforum.com](http://www.eigenkapitalforum.com).

Mr Svoboda is available for meetings with investors. To schedule a meeting, please contact Marianne Sengupta ([marianne.sengupta@elanix-bt.com](mailto:marianne.sengupta@elanix-bt.com)).

Elanix will also be presenting at the following upcoming investor events:

- Mid Small Cap Forum, 13-14 December 2017, Milan
- Biomedtech Event, 19 December 2017, Paris

**Elanix Biotechnologies AG** develops and commercializes tissue regeneration products for wound care, dermatological and gynecological applications, and provides services in cell technologies. The company was founded in 2012 as a spin-out from the University Hospital of Lausanne (CHUV), Switzerland, to commercialize a patented human progenitor cell technology. Progenitor cells are fully differentiated yet immunologically neutral cells that are very potent inducers of tissue growth and healing. Elanix Biotechnologies owns GMP certified Master and Working human cell banks with vast quantities of cells.

Elanix Biotechnologies AG has its registered office in Berlin, Germany, with an office in Wiesbaden, Germany, and operational headquarters in Nyon, Switzerland. It is listed in the Regulated Market (General Standard) on the Frankfurt Stock Exchange under the ISIN DE000A0WMJQ4 (symbol ELN). Further information can be found at [www.elanixbiotechnologies.com](http://www.elanixbiotechnologies.com).

**Press Contacts:**

Elanix Biotechnologies

Halsin Partners

Tomas Svoboda, CEO

Mike Sinclair

Tel: +41 22 363 66 40

Tel: +44 (0)20 7318 2955

investor.relations@elanix-bt.com

msinclair@halsin.com

**Forward-looking statements**

This publication contains forward-looking statements subject to certain risks and uncertainties. Actual results may be materially different from those expressed or implied by such statements due to a variety of risk factors and uncertainties, such as changes in the business, economic and competitive situation, exchange rate fluctuations, uncertainties regarding litigation or investigation proceedings and the availability of financial resources. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. Elanix Biotechnologies AG disclaims any obligation to update these forward-looking statements.